Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice. Cancer Research 2015, 75: 3466-3478. PMID: 26113085, DOI: 10.1158/0008-5472.can-14-3510.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalColorectal NeoplasmsDNA-Binding ProteinsGraft vs Host DiseaseHT29 CellsHumansInterleukin Receptor Common gamma SubunitLeukocytes, MononuclearLymphocyte ActivationMiceNivolumabProgrammed Cell Death 1 ReceptorT-LymphocytesTumor Necrosis Factor Receptor Superfamily, Member 9ConceptsPeripheral blood mononuclear cellsT lymphocytesHuman T lymphocytesAllogeneic human peripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsT cell-mediated diseaseImmune checkpoint drugsImmunostimulatory monoclonal antibodiesCell-mediated diseaseRegulatory T lymphocytesHumanized murine modelBlood mononuclear cellsHumanized mouse modelPreclinical model systemsLymphocyte infiltrationTherapeutic regimenMononuclear cellsCell surface expressionCancer immunologyGastric carcinomaImmunodeficient miceMurine modelMouse modelSame patientTumor xenografts